Table 2.
Prevalence of abnormal glucose metabolism and other endocrine disorders in β-thalassemia major classified by study region.
| Region | DM | IFG | IGT | EnD | ||||
|---|---|---|---|---|---|---|---|---|
| P (%) | 95% CI (%) | P (%) | 95% CI (%) | P (%) | 95% CI (%) | P (%) | 95% CI (%) | |
| Mediterranean coast | 5.36 | 3.95-6.77 | 6.52 | 5.74-7.30 | 15.16 | 3.56-26.76 | 39.82 | 33.55-46.10 |
| Middle East | 7.90 | 5.75-10.05 | 27.88 | 18.50-37.26 | 7.14 | 0.13-14.15 | 36.67 | 31.22-42.11 |
| Europe | 6.05 | 2.82-9.28 | NR | NR | 14.01 | 8.56-19.45 | 65.98 | 56.61-75.35 |
| America | 12.77 | 7.24-18.31 | NR | NR | NR | NR | 27.50 | 24.67-30.32 |
| Asia | 6.38 | 2.75-10.01 | 18.29 | 5.67-30.91 | 9.07 | 4.97-13.16 | 55.06 | 44.80-65.32 |
| Oceania | 18.18 | 6.78-29.58 | NR | NR | NR | NR | NR | NR |
| Overall | 6.54 | 5.30-7.78 | 17.21 | 8.43-26.00 | 12.46 | 5.98-18.94 | 43.92 | 37.94-49.89 |
DM: diabetes mellitus; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; EnD: endocrine disorders; P: prevalence; 95% CI: 95% confidence interval; NR: not reported.